CureVac, a German Phase 1 biotech developing an mRNA vaccine for SARS-CoV-2, raised $213 million by offering 13.3 million shares at $16, the high end of the range of $14 to $16. The company raised an additional $118 million in a concurrent private placement to insider Dietmar Hopp.
CureVac plans to list on the Nasdaq under the symbol CVAC. BofA Securities, Jefferies, Credit Suisse, Berenberg and Kempen acted as lead managers on the deal.
